Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
about
Lessons from mouse models of high-fat diet-induced NAFLDEzetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes.NPC1L1 and cholesterol transportDietary cholesterol reverses resistance to diet-induced weight gain in mice lacking Niemann-Pick C1-Like 1.Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease.Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.Nuciferine prevents hepatic steatosis and injury induced by a high-fat diet in hamsters.Effective therapy using voglibose for nonalcoholic steatohepatitis in a patient with insufficient dietary and exercise therapy: exploring other treatment possibilities.Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distributionCholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease.Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammationNiemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Emerging drugs for non-alcoholic steatohepatitis.Intestinal and hepatic niemann-pick c1-like 1.Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice.Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Role of ezetimibe in non-alcoholic fatty liver disease.Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review.Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats.A specific Streptococcus mutans strain aggravates non-alcoholic fatty liver disease.Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferaseCurrent pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse.Longitudinal comparison of Streptococcus mutans-induced aggravation of non-alcoholic steatohepatitis in mice.
P2860
Q26829532-D3551CB9-A25A-424A-BEF6-79DC645033B1Q33609823-51B0973D-6FCB-4A14-98C7-CA8D824FF218Q34019608-A48AC623-E9EF-4A18-BE11-F4E8649F2EAFQ34116347-5AF0BD34-72BC-44E4-B6DF-F713830A18FAQ34160784-24E8F538-47CE-4C4A-ABAE-9219FA5DF285Q34487963-9B6FA599-45B9-4D61-8911-7C49B926F504Q34730964-826497ED-79CA-401F-B6A5-DA7190F4770EQ35071369-9A7BE83D-08F4-4576-BAFE-877438333B89Q35293633-561BB29E-EF52-4884-8CA5-CA753C345855Q35871671-9B9F6C96-46BF-4D8D-8A61-2EABB2FBB797Q36237764-ECFD87BA-9540-49A2-99E7-9F5912583CD7Q36296929-150269DA-917C-4EAA-9A78-52E2610E7BF6Q36302750-4779703C-4765-4631-B87D-3151ABED9EE7Q37662878-1A022A3F-1944-4B70-B0C7-D2D0BB4F6A73Q37857866-67AC4F48-66D0-4243-958F-A4F4FAC67BC1Q37926944-81C040B2-4B11-4388-8A8C-BE590FBD90ECQ37978785-CBB1CB54-5F7C-4025-89AC-E456882725C5Q38121137-92E1F841-ADC6-4E4D-BBD0-461896D6C094Q38132749-6F12AFF2-739A-4D54-8F83-1FAC8D37A0FFQ38331528-70093225-6CB8-4DC9-92F1-18747CA16614Q38782562-2AB49EBD-892B-4676-86C9-7E0F9755EF55Q38941024-1D68E407-9635-416A-B23E-8FB485D11540Q39341139-25498949-0BE1-40D2-806B-2B6BA6B1C4E6Q41195503-679CEF89-EB4E-436E-85C8-0BC0358B1B0CQ41682321-50403F2D-20A0-4EC2-9CDF-92393097CB71Q41776542-FD9E3A6B-DE8B-4322-B254-9C2381C4C436Q43217282-DABA3691-7559-492E-B029-CFF0968A6818Q46754499-84D3D253-A37F-4C3C-8FAE-17F89B985BA6Q52674828-BAE735E6-F7AF-4A3B-ADEE-C31AC81E8A31
P2860
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Long-term combination therapy ...... alcoholic fatty liver disease.
@en
type
label
Long-term combination therapy ...... alcoholic fatty liver disease.
@en
prefLabel
Long-term combination therapy ...... alcoholic fatty liver disease.
@en
P2093
P1476
Long-term combination therapy ...... alcoholic fatty liver disease.
@en
P2093
Atsushi Nakajima
Hirokazu Takahashi
Hiroyuki Kirikoshi
Kensuke Kubota
Koichiro Wada
Koji Fujita
Masahiko Inamori
Masato Yoneda
Naohiko Masaki
Satoru Saito
P304
P356
10.1016/J.JHEP.2009.05.017
P577
2009-06-06T00:00:00Z